Analysis of recombinant mycobacteria as T helper type 1 vaccines in an allergy challenge model

Immunology

Volumn 102, Issue 4, 2001, Pages 441-449

  Janssen, R ^a,b,d   Kruisselbrink, A ^a   Hoogteijling, L ^a   Lamb, J R ^c   Young, D B ^b   Thole, J E R ^a  

^a TNO   (Netherlands)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIBODY; BCG VACCINE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 5; LIVE VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT VACCINE;

ALLERGY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; MOUSE; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; BACTERIAL VACCINES; FEMALE; GLYCOPROTEINS; IMMUNOGLOBULIN G; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MITES; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; SPECIES SPECIFICITY; SPLEEN; TH1 CELLS; TH2 CELLS; VACCINES, SYNTHETIC;

EID: 0035055272     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2001.01207.x     Document Type: Article

References (42)

1. A potential vaccine strategy for asthma and allied atopic diseases during early childhood
2. The BCG experience: Implications for future vaccines against tuberculosis
3. Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production
4. Human T cell responses induced by vaccination with Mycobacterium bovis bacillus Calmette-Guerin
5. In Th2-biased lymphatic filarial patients, responses to purified protein derivative of Mycobacterium tuberculosis remain Th1
6. Patterns of cytokine production by mycobacterium-reactive human T-cell clones
7. Variation in protection by BCG. Implications of and for heterologous immunity
8. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi
9. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines
10. New use of BCG for recombinant vaccines
11. Development of BCG as a recombinant vaccine vehicle
12. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: A candidate Lyme disease vaccine
13. Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia
14. The inverse association between tuberculin responses and atopic disorder
15. Early BCG vaccination and development of atopy
16. Prevalence of allergy in children in relation to prior BCG vaccination and infection with atypical mycobacteria
17. Comparison of antigen presentation by lymph node cells from protein and peptide-primed mice
18. Characterization of T-cell responses to the house dust mite allergen Der p II in mice. Evidence for major and cryptic epitopes
19. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration
20. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: A randomised controlled trial
21. Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae
22. Transformation of mycobacterial species using hygromycin resistance as selectable marker
23. An Epitope Delivery System for Use with Recombinant Mycobacteria
24. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4
25. Mycobacterial protein antigens: A compilation
26. Sequence polymorphisms of cDNA clones encoding the mite allergen Der p I
27. Prediction of murine MHC class I epitopes in a major house dust mite allergen and reduction of T1-type CD8+ T cell responses
28. Induction of T cell responses to the invariant chain derived peptide CLIP in mice immunized with the group 1 allergen of house dust mite
29. IL-4-deficient Balb/c mice resist infection with Leishmania major
30. Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection
31. Infections and the development of allergy
32. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae
33. T cell genetic background determines maintenance of IL-12 signaling: Effects on BALB/c and B10.D2 T helper cell type 1 phenotype development
34. Tpm1, a locus controlling IL-12 responsiveness, acts by a cell-autonomous mechanism
35. The host response to Calmette-Guerin bacillus infection in mice
36. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines
37. CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity
38. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma
39. BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model
40. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses
41. Rush immunotherapy results in allergen-specific alterations in lymphocyte function and interferon-gamma production in CD4+ T cells
42. IL-5 production by allergen-stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis